Voyager Therapeutics, Inc. (VYGR) DCF Valuation

Voyager Therapeutics, Inc. (VYGR) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Voyager Therapeutics, Inc. (VYGR) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Looking to determine the intrinsic value of Voyager Therapeutics, Inc. (VYGR)? Our (VYGR) DCF Calculator integrates real-world data with comprehensive customization features, enabling you to adjust forecasts and enhance your investment choices.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 104.4 171.1 37.4 40.9 250.0 309.5 383.1 474.2 586.9 726.5
Revenue Growth, % 0 63.93 -78.14 9.33 511.16 23.78 23.78 23.78 23.78 23.78
EBITDA -48.9 31.2 -68.5 -44.6 126.5 -110.2 -136.4 -168.8 -209.0 -258.7
EBITDA, % -46.86 18.23 -182.96 -109.14 50.58 -35.61 -35.61 -35.61 -35.61 -35.61
Depreciation 2.8 3.8 5.2 6.2 4.4 22.0 27.3 33.8 41.8 51.7
Depreciation, % 2.65 2.23 13.8 15.13 1.78 7.12 7.12 7.12 7.12 7.12
EBIT -51.7 27.4 -73.6 -50.8 122.0 -114.3 -141.5 -175.2 -216.8 -268.4
EBIT, % -49.51 16 -196.76 -124.27 48.8 -36.94 -36.94 -36.94 -36.94 -36.94
Total Cash 281.5 181.1 132.5 118.8 230.9 304.7 377.2 466.9 577.9 715.4
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 18.7 8.0 .7 .6 84.5
Account Receivables, % 17.91 4.68 2 1.56 33.78
Inventories 2.2 6.9 1.7 .8 .0 7.8 9.7 12.0 14.8 18.4
Inventories, % 2.11 4.06 4.57 1.9 0 2.53 2.53 2.53 2.53 2.53
Accounts Payable 4.1 .6 .6 2.6 1.6 7.9 9.7 12.1 14.9 18.5
Accounts Payable, % 3.9 0.37048 1.53 6.27 0.64158 2.54 2.54 2.54 2.54 2.54
Capital Expenditure -7.7 -12.1 -1.6 -2.5 -3.3 -16.2 -20.0 -24.8 -30.7 -38.0
Capital Expenditure, % -7.39 -7.07 -4.3 -6.09 -1.3 -5.23 -5.23 -5.23 -5.23 -5.23
Tax Rate, % 1.05 1.05 1.05 1.05 1.05 1.05 1.05 1.05 1.05 1.05
EBITAT -48.4 27.4 -68.3 -50.9 120.7 -111.0 -137.4 -170.0 -210.5 -260.5
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -70.2 21.6 -52.3 -44.1 37.9 -59.3 -138.9 -172.0 -212.9 -263.5
WACC, % 8.32 8.34 8.31 8.34 8.33 8.33 8.33 8.33 8.33 8.33
PV UFCF
SUM PV UFCF -639.7
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -269
Terminal Value -4,247
Present Terminal Value -2,847
Enterprise Value -3,487
Net Debt -49
Equity Value -3,438
Diluted Shares Outstanding, MM 45
Equity Value Per Share -77.14

What You Will Get

  • Real VYGR Financials: Access to historical and projected data for precise valuation.
  • Customizable Inputs: Adjust parameters like WACC, tax rates, revenue growth, and capital expenditures.
  • Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
  • Scenario Analysis: Evaluate various scenarios to assess Voyager’s future performance.
  • User-Friendly Design: Designed for professionals while remaining accessible to newcomers.

Key Features

  • Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for Voyager Therapeutics, Inc. (VYGR).
  • WACC Calculator: Pre-built Weighted Average Cost of Capital sheet with adjustable inputs specific to the biotech sector.
  • Customizable Forecast Assumptions: Easily adjust growth rates, research and development expenses, and discount rates.
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios for Voyager Therapeutics, Inc. (VYGR).
  • Interactive Dashboard and Charts: Visual representations summarize key valuation metrics for streamlined analysis.

How It Works

  • Download: Obtain the pre-formatted Excel file containing Voyager Therapeutics, Inc.'s (VYGR) financial data.
  • Customize: Modify projections such as revenue growth, EBITDA %, and WACC to fit your analysis.
  • Update Automatically: Watch as intrinsic value and NPV calculations refresh in real-time.
  • Test Scenarios: Develop various projections and instantly compare the results.
  • Make Decisions: Leverage the valuation insights to inform your investment choices.

Why Choose This Calculator?

  • Designed for Experts: A sophisticated tool utilized by researchers, investment analysts, and biotech professionals.
  • Comprehensive Data: Voyager Therapeutics’ historical and projected financials are preloaded for precise analysis.
  • Flexible Scenario Analysis: Easily simulate various forecasts and assumptions to assess different outcomes.
  • Insightful Outputs: Automatically computes intrinsic value, NPV, and essential metrics for informed decision-making.
  • User-Friendly: Step-by-step guidance ensures a smooth experience throughout the calculation process.

Who Should Use This Product?

  • Professional Investors: Develop comprehensive and trustworthy valuation models for portfolio assessments of Voyager Therapeutics, Inc. (VYGR).
  • Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within their organizations.
  • Consultants and Advisors: Deliver precise valuation insights for clients interested in Voyager Therapeutics, Inc. (VYGR).
  • Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
  • Biotech Enthusiasts: Gain insights into how biotech firms like Voyager Therapeutics, Inc. (VYGR) are assessed in the financial landscape.

What the Template Contains

  • Pre-Filled DCF Model: Voyager Therapeutics’ financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
  • Financial Ratios: Evaluate Voyager Therapeutics’ profitability, leverage, and efficiency.
  • Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
  • Financial Statements: Annual and quarterly reports to support detailed analysis.
  • Interactive Dashboard: Easily visualize key valuation metrics and results.

No products were found matching.